<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949075</url>
  </required_header>
  <id_info>
    <org_study_id>H-18016341</org_study_id>
    <nct_id>NCT03949075</nct_id>
  </id_info>
  <brief_title>Impact of Angiotensin Converting Enzyme Activity on Exercise Training Sensitivity</brief_title>
  <official_title>Impact of Angiotensin Converting Enzyme Activity on Exercise Training Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The phenotype based on the insertion/deletion (I/D) polymorphism of the human angiotensin
      converting enzyme (ACE) gene has been associated with individual training response. Briefly,
      intervention studies have demonstrated an 11-fold greater training-induced improvement in
      muscular endurance for ACE I/I homozygotes compared to ACE D/D homozygotes.

      Importantly, the ACE I/D polymorphism causes large inter-individual differences in serum ACE
      activity. Because the ACE D/D genotype is characterized by high plasma ACE activity and
      potentially blunted endurance exercise training response, it appears likely that ACE
      inhibitors (ACEi) have the potential to improve the outcome of exercise training for ACE D/D
      homozygotes.

      Thus, in the present study the investigators apply a randomized double-blind
      placebo-controlled longitudinal design to investigate whether pharmacological inhibition of
      ACE activity can amplify the exercise training response in healthy humans carrying either the
      ACE D/D or ACE I/I genotype.

      The study hypothesis is that inhibition of ACE activity in healthy humans with the ACE D/D
      genotype will amplify the health beneficial effects of exercise training while this is not
      the case in ACE I/I homozygotes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The present study is double-blinded with regard to ACE genotype and study medication and the blinding is kept until completion of the trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal systemic oxygen uptake</measure>
    <time_frame>20 minutes</time_frame>
    <description>Training-induced changes in maximal systemic oxygen uptake (L/min) is evaluated with an incremental maximal cycle protocol on a cycle ergometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal muscle endurance</measure>
    <time_frame>5 minutes</time_frame>
    <description>Training-induced changes in muscle endurance evaluated as changes in duration (sec) of a repetitive elbow-flexion exercise</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood volume</measure>
    <time_frame>20 minutes</time_frame>
    <description>Training-induced changes in total blood volume (mL) is measured using the Carbon-monoxide rebreathing method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endurance performance</measure>
    <time_frame>15 minutes</time_frame>
    <description>Training-induced changes in endurance performance is determined by a 2000 meter time trial on an indoor rowing ergometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle oxidative capacity</measure>
    <time_frame>60 minutes</time_frame>
    <description>Training-induced changes in muscle oxidative capacity is evaluated as maximal citrate synthase and 3- hydroxy-acetylCoa-dehydrogenase activity (µmol/g/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial biogenesis</measure>
    <time_frame>60 minutes</time_frame>
    <description>Expression of complex I-V will be analyzed in order to evaluate if the applied training induced mitochondrial biogenesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP)</measure>
    <time_frame>10 minutes</time_frame>
    <description>Training-induced changes in resting MAP (mmHg) will be estimated using this formula: MAP = diastolic pressure + 1/3 (systolic pressure - diastolic pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state systemic oxygen uptake</measure>
    <time_frame>10 minutes</time_frame>
    <description>Training-induced changes in steady-state systemic oxygen uptake (mL/min) is determined by indirect calorimetry during a submaximal cycle protocol on a cycle ergometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>1 minute</time_frame>
    <description>Training-induced changes in muscle strength (kg) is measured using a handgrip dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass</measure>
    <time_frame>20 minutes</time_frame>
    <description>Training-induced changes in fat mass (kg) is determined by dual-energy x-ray absorptiometry (DXA)-scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat free mass</measure>
    <time_frame>20 minutes</time_frame>
    <description>Training-induced changes in fat free mass (kg) is determined by DXA-scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat percentage</measure>
    <time_frame>20 minutes</time_frame>
    <description>Training-induced changes in body fat percentage (%) is determined by DXA-scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular (LV) mass</measure>
    <time_frame>45 minutes</time_frame>
    <description>Training-induced changes in LV mass (g) is determined by cardiac magnetic resonance imaging (cMRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV end-diastolic volume</measure>
    <time_frame>45 minutes</time_frame>
    <description>Training-induced changes in LV end-diastolic volume (mL) is determined by cMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV mean wall thickness</measure>
    <time_frame>45 minutes</time_frame>
    <description>Training-induced changes in LV mean wall thickness (cm) is determined by cMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV stroke volume</measure>
    <time_frame>45 minutes</time_frame>
    <description>Training-induced changes in LV stroke volume (mL) is determined by cMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV ejection fraction</measure>
    <time_frame>45 minutes</time_frame>
    <description>LV stroke volume (mL) and LV end-diastolic volume (mL) will be used to measure training-induced changes in LV ejection fraction (%)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ACE activity</measure>
    <time_frame>10 minutes</time_frame>
    <description>Obtained blood samples will be analyzed for ACE activity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Exercise</condition>
  <condition>Angiotensin-Converting Enzyme Inhibitors</condition>
  <arm_group>
    <arm_group_label>Enalapril treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>Participants will be assigned to daily administration of ACE inhibitors (Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response) combined with an 8-week training period.</description>
    <arm_group_label>Enalapril treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.</description>
    <arm_group_label>Placebo treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ACE I/I or ACE D/D homozygote

          -  Aged 20-50 years

          -  Healthy

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolai B Nordsborg, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nikolai B Nordsborg, phD</last_name>
    <phone>+45 35321612</phone>
    <email>nbn@nexs.ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tórur Sjúrðarson, Msc</last_name>
    <phone>+298 519568</phone>
    <email>ts@nexs.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nutrition, Exercise and Sports</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990 Oct;86(4):1343-6.</citation>
    <PMID>1976655</PMID>
  </reference>
  <reference>
    <citation>Montgomery HE, Marshall R, Hemingway H, Myerson S, Clarkson P, Dollery C, Hayward M, Holliman DE, Jubb M, World M, Thomas EL, Brynes AE, Saeed N, Barnard M, Bell JD, Prasad K, Rayson M, Talmud PJ, Humphries SE. Human gene for physical performance. Nature. 1998 May 21;393(6682):221-2.</citation>
    <PMID>9607758</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>May 18, 2019</last_update_submitted>
  <last_update_submitted_qc>May 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Nikolai Nordsborg</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Adaptation, Physiological</keyword>
  <keyword>Genotype</keyword>
  <keyword>Polymorphism, Genetic</keyword>
  <keyword>Enalapril</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Fully anonymous data will be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

